Gain Therapeutics, INC 10-Q quarterly reports

Gain Therapeutics reported continued net losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern, even as its lead Parkinson's drug candidate, rexaceract, progresses through clinical trials.

Gain Therapeutics reports increased operating expenses in Q1 2026, with a net loss of $5.6 million, and highlights substantial doubt about its ability to continue as a going concern.

Gain Therapeutics reported a net loss of $15.6 million for the nine months ended September 30, 2025, while extending its Phase 1b Parkinson's disease study due to positive participant retention.

Gain Therapeutics reported a reduced net loss in Q2 2025, driven by lower operating expenses, but faces substantial doubt about its ability to continue as a going concern beyond Q1 2026 despite recent capital raises.

Gain Therapeutics reports a net loss of $4.53 million for Q1 2025, with ongoing efforts to advance its clinical programs and secure additional funding amid going concern uncertainties.

Gain Therapeutics' Q3 2024 report highlights ongoing clinical trials and financial challenges, including a going concern warning.

Gain Therapeutics reports its Q2 2024 financial results, highlighting ongoing losses and raising substantial doubt about its ability to continue as a going concern.

Gain Therapeutics reported its first quarter 2024 financial results, highlighting progress in clinical trials but also raising concerns about its ability to continue as a going concern.